| |
Centre for Policy on Ageing | |
 | |
|
| Guidance on the use of taxanes for ovarian cancer | | Corporate Author | National Institute for Clinical Excellence - NICE |
| Publisher | National Institute for Clinical Excellence, London, May 2000 |
| Pages | 8 pp (Technology appraisal guidance, no 3) |
| Source | National Institute for Clinical Excellence, 90 Long Acre, Covent Garden, London WC2E 9RZ. |
| Keywords | Older women ; Cancer ; Drugs ; Standards of provision. |
| Annotation | There are two Taxane drugs available in the UK : docetaxol (Taxotere, not currently licensed in the UK for primary treatment of ovarian cancer) and paclitaxel (Taxol). This guidance outlines clinical need and practice, the technology, evidence, implications for the NHS, further research, implementation, and clinical audit advice. Appendix C - Patient information - is designed to support production of information leaflets, and explains cancer, where taxane drugs fit in, and what NICE have recommended about their use. This guidance represents the views of the Institute's Appraisal Committee, which was arrived at after careful consideration of the available evidence. The guidance will be reviewed in March 2001. (RH). |
| Accession Number | CPA-000519002 P |
| Classmark | BD: CK: LLD: 583 * |
Data © Centre for Policy on Ageing |
|
| ...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|